Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Article Types

Countries / Regions

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Search Results (676)

Search Parameters:
Keywords = toxoplasma

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
21 pages, 2457 KB  
Article
BthTX-II, an Asp49 PLA2 from Bothrops jararacussu, Impairs Toxoplasma gondii Infection: In Vitro and Ex Vivo Approaches
by Vinícius Queiroz Oliveira, Emanuelle Lorrayne Ferreira, Lorena Pinheiro Morais, Leonardo Alves Garcia, Gabriel de Oliveira Sousa, Marcos Paulo Oliveira Almeida, Guilherme de Souza, Joed Pires de Lima Júnior, Natália Carine Lima dos Santos, Rafael Martins de Oliveira, Tássia Rafaela Costa, Andreimar Martins Soares, Luísa Carregosa Santos, Daiana Silva Lopes, Emidio Beraldo-Neto, Angelica Oliveira Gomes, Jovita Eugênia Gazzinelli Cruz Madeira, Bellisa Freitas Barbosa, Eloisa Amália Vieira Ferro, Samuel Cota Teixeira and Veridiana de Melo Rodrigues Ávilaadd Show full author list remove Hide full author list
Pharmaceuticals 2025, 18(9), 1260; https://doi.org/10.3390/ph18091260 (registering DOI) - 25 Aug 2025
Abstract
Background/Objectives: Toxoplasma gondii, an obligate intracellular parasite, poses a major global health concern owing to its potential for congenital transmission, particularly during pregnancy. Current pharmacological treatments, including spiramycin and pyrimethamine, exhibit limitations in both efficacy and safety, underscoring the need for [...] Read more.
Background/Objectives: Toxoplasma gondii, an obligate intracellular parasite, poses a major global health concern owing to its potential for congenital transmission, particularly during pregnancy. Current pharmacological treatments, including spiramycin and pyrimethamine, exhibit limitations in both efficacy and safety, underscoring the need for novel therapeutic strategies. In this study, we investigated the antiparasitic potential of BthTX-II, an Asp49 phospholipase A2 (PLA2) isolated from Bothrops jararacussu venom, in human trophoblast cells (BeWo) and third-trimester human placental explants infected with T. gondii. Methods: In vitro assays were performed using BeWo cells infected with T. gondii tachyzoites and treated with non-cytotoxic concentrations of BthTX-II (3.125, 1.56, and 0.78 µg/mL). An ex vivo model employing third-trimester human placental villous explants was used under similar conditions. Parasite proliferation, adhesion, and invasion were assessed alongside host immune response modulation. Results: Our findings demonstrate that BthTX-II reduces T. gondii proliferation in BeWo cells at all tested non-cytotoxic concentrations. The toxin also significantly impaired parasite adhesion and invasion while modulating host immune response by upregulating interleukin (IL)-6, IL-8, and macrophage migration inhibitory factor (MIF), and downregulating vascular endothelial growth factor—potentially disrupting parasite proliferation. In placental villous explants, BthTX-II (1.56 μg/mL) reduced T. gondii proliferation and modulated IL-8, MIF, and tumour necrosis factor-alpha levels without compromising tissue viability. Conclusions: These findings highlight BthTX-II as a potential candidate in toxoplasmosis treatment. Further investigation should focus on its dual role in limiting parasite development and modulating immune responses at the maternal–fetal interface. Full article
(This article belongs to the Special Issue Recent Research in Therapeutic Potentials of Venoms)
Show Figures

Figure 1

14 pages, 1570 KB  
Article
The Distribution of Neospora caninum Secretory Proteins in Mouse and Calf Brains
by Nanako Ushio-Watanabe, Rio Fujihara, Kenichi Watanabe, Manabu Yamada, Yoshiyasu Kobayashi and Yoshifumi Nishikawa
Microorganisms 2025, 13(9), 1970; https://doi.org/10.3390/microorganisms13091970 - 22 Aug 2025
Viewed by 74
Abstract
Neospora caninum, as well as Toxoplasma gondii, secrete proteins that facilitate the invasion of host cells and the regulation of host immune response and metabolism. However, the localization of the secretory proteins in infected animal brains has not been studied in [...] Read more.
Neospora caninum, as well as Toxoplasma gondii, secrete proteins that facilitate the invasion of host cells and the regulation of host immune response and metabolism. However, the localization of the secretory proteins in infected animal brains has not been studied in detail. Here, we investigate the brain and intracellular distribution of the secretory proteins in experimentally infected mice and naturally infected calves through histopathology and immunohistochemistry (IHC) to detect surface antigen 1 (NcSAG1), cyclophilin (NcCYP), profilin (NcPF), dense granule protein 6 (NcGRA6), and NcGRA7. These methods revealed that numerous tachyzoites positive for NcSAG1, NcCYP, NcPF, NcGRA6, and NcGRA7 were localized in and around the animals’ necrotic lesions, and NcGRA7 was diffusely observed in the necrotic lesions of the infected mice. Moreover, IHC revealed that NcGRA6 and NcGRA7 were distributed in the cytoplasm of infected neurons around the parasites in the infected mice and calves. This suggests that NcGRA6 and NcGRA7 might be directly related to the alteration of neuronal metabolism and activity, and that NcGRA7 might be related to the formation of necrotic lesions. Full article
(This article belongs to the Special Issue Advances in Veterinary Microbiology)
Show Figures

Figure 1

18 pages, 1464 KB  
Article
Killer Peptide-Containing Polyelectrolytic Nanocomplexes to Fight Toxoplasma gondii Infection
by Arianna Bucella, Manuela Semeraro, Laura Giovati, Lorenza Artesani, Ruggero Bettini, Annalisa Bianchera and Alice Vismarra
Pharmaceutics 2025, 17(8), 1075; https://doi.org/10.3390/pharmaceutics17081075 - 20 Aug 2025
Viewed by 203
Abstract
Background/Objectives: Toxoplasmosis, a zoonotic disease caused by Toxoplasma gondii, typically is asymptomatic in immunocompetent individuals but causes severe complications in immunocompromised subjects and during pregnancy. Current treatments such as pyrimethamine and sulfadiazine are effective for acute infections but cannot eliminate encysted bradyzoites [...] Read more.
Background/Objectives: Toxoplasmosis, a zoonotic disease caused by Toxoplasma gondii, typically is asymptomatic in immunocompetent individuals but causes severe complications in immunocompromised subjects and during pregnancy. Current treatments such as pyrimethamine and sulfadiazine are effective for acute infections but cannot eliminate encysted bradyzoites and have significant side effects. The antimicrobial killer peptide (KP) has interesting therapeutic potential, but its intracellular delivery is challenging; hyaluronate-based nanoparticles loaded with KP (KP-NPs) were evaluated to target T. gondii-infected cells that overexpress CD44. Methods: KP-NPs made of chitosan and hyaluronate were produced by microfluidics and were characterized for size, surface charge, encapsulation efficiency, and stability under stress conditions. After excluding their toxicity, their activity was tested in vitro against Candida albicans and T. gondii as free tachyzoite or in infected human foreskin fibroblasts (HFFs). Results: KP was efficiently encapsulated in nanoparticles and protected from harsh acidic conditions at high temperature. Preliminary in vitro testing against C. albicans showed that, at the lowest candidacidal concentration of KP (2.5 μg/mL), KP-NPs killed 90.97% of yeast cells. KP itself proved to be non-toxic for HFFs as host cells and effective against T. gondii. Comparable results were obtained for KP-NPs and blank nanoparticles (BLK-NPs), with no observed toxicity to host cells, confirming that encapsulation did not alter peptide efficacy. The parasiticidal effect of KP alone, as well as KP-NPs at 250 µg/mL and BLK-NPs, was confirmed through tests on free T. gondii tachyzoites. Reduction rates for the number of infected cells ranged from 66% to 90% with respect to control, while the reduction in the number of intracellular tachyzoites ranged from 66% to 80%. Interestingly, KP alone was not effective against intracellular tachyzoite, while KP-NPs maintained an efficacy comparable to the extracellular model, suggesting that particles helped the internalization of the peptide. Conclusions: Encapsulation of KP into hyaluronate/chitosan nanoparticles does not alter its activity and improves its efficacy against the intracellular parasite. Notably, BLK-NPs appeared to exhibit efficacy against the parasite on its own, without the presence of KP. Full article
(This article belongs to the Section Nanomedicine and Nanotechnology)
Show Figures

Figure 1

25 pages, 2958 KB  
Article
Brazilian Red Propolis and Its Active Constituent 7-O-methylvestitol Impair Early and Late Stages of Toxoplasma gondii Infection in Human Placental Models
by Samuel Cota Teixeira, Guilherme de Souza, Natalia Carine Lima dos Santos, Rafael Martins de Oliveira, Nagela Bernadelli Sousa Silva, Joed Pires de Lima Junior, Alessandra Monteiro Rosini, Luana Carvalho Luz, Aryani Felixa Fajardo Martínez, Marcos Paulo Oliveira Almeida, Guilherme Vieira Faria, Rosiane Nascimento Alves, Angelica Oliveira Gomes, Maria Anita Lemos Vasconcelos Ambrosio, Rodrigo Cassio Sola Veneziani, Jairo Kenupp Bastos, José Roberto Mineo, Carlos Henrique Gomes Martins, Eloisa Amália Vieira Ferro and Bellisa Freitas Barbosa
Microorganisms 2025, 13(8), 1937; https://doi.org/10.3390/microorganisms13081937 - 20 Aug 2025
Viewed by 247
Abstract
Toxoplasma gondii is a globally distributed protozoan parasite and a major cause of congenital infections, particularly in South America. Current therapies for congenital toxoplasmosis are limited by toxicity, long treatment regimens, and suboptimal efficacy, highlighting the urgent need for safer and more effective [...] Read more.
Toxoplasma gondii is a globally distributed protozoan parasite and a major cause of congenital infections, particularly in South America. Current therapies for congenital toxoplasmosis are limited by toxicity, long treatment regimens, and suboptimal efficacy, highlighting the urgent need for safer and more effective alternatives. In this study, we evaluated the antiparasitic effects of crude ethanolic extract of Brazilian Red Propolis (BRP) and its isolated compounds, focusing on 7-O-methylvestitol, in human trophoblast (BeWo) cells and third-trimester placental explants. Both BRP and 7-O-methylvestitol significantly reduced T. gondii adhesion, invasion, and intracellular replication, without compromising host cell viability. Ultrastructural analyses revealed irreversible parasite damage, and cytokine profiling demonstrated immunomodulatory effects, with enhanced production of interleukin (IL)-6, IL-8, and macrophage migration inhibitory factor (MIF) in BeWo cells and downregulation of IL-6, MIF, and tumor Necrosis Factor (TNF) in infected placental villi. Notably, 7-O-methylvestitol reproduced and, in some assays, surpassed the antiparasitic activity of BRP, suggesting it as a key bioactive constituent responsible for the therapeutic potential of the extract. These findings support the identification of 7-O-methylvestitol as a promising lead compound for structure-based drug design and repositioning strategies, advancing the development of novel, safe, and targeted therapies against congenital toxoplasmosis. Full article
(This article belongs to the Special Issue Advances in Toxoplasma gondii and Toxoplasmosis)
Show Figures

Figure 1

42 pages, 1635 KB  
Review
Review of Toxoplasmosis: What We Still Need to Do
by Muhammad Farhab, Muhammad Waqar Aziz, Aftab Shaukat, Ming-Xing Cao, Zhaofeng Hou, Si-Yang Huang, Ling Li and Yu-Guo Yuan
Vet. Sci. 2025, 12(8), 772; https://doi.org/10.3390/vetsci12080772 - 18 Aug 2025
Viewed by 414
Abstract
Toxoplasma gondii is responsible for the disease toxoplasmosis and has the broadest host range among apicomplexan parasites, as it infects virtually all warm-blooded vertebrates. Toxoplasmosis is a zoonotic and emerging public health concern with considerable morbidity and mortality, especially in the developing world, [...] Read more.
Toxoplasma gondii is responsible for the disease toxoplasmosis and has the broadest host range among apicomplexan parasites, as it infects virtually all warm-blooded vertebrates. Toxoplasmosis is a zoonotic and emerging public health concern with considerable morbidity and mortality, especially in the developing world, affecting approximately one-third of the world’s human population. Clinical presentation varies among species, and the infection establishes lifelong chronicity in hosts. Most of the host species (including healthy humans) are asymptomatic on the one hand, it is fatal to marsupials, neotropical primates and some marine mammals on the other hand. In immunocompetent humans, infection is typically asymptomatic, whereas immunocompromised individuals may develop disseminated disease affecting virtually any organ system—most commonly reproductive, cerebral, and ocular systems. Toxoplasmosis spreads by ingestion of food or water contaminated with T. gondii oocysts, consumption of undercooked/raw meat containing tissue cysts, transplacental transmission from mother to fetus, or by receiving infected organ/blood from the infected individual. Toxoplasmosis is mainly diagnosed by serologic tests and polymerase chain reaction (PCR). It is treated with pyrimethamine combined with sulfadiazine or clindamycin, often supplemented with leucovorin, atovaquone, and dexamethasone. Despite having many potent anti-T. gondii antigenic candidates, there is no commercially available vaccine for humans due to many factors, including the complex life cycle of the parasite and its evasion strategies. To date, the only commercially available anti-T. gondii vaccine is for sheep, licensed for veterinary use to prevent ovine abortions. In this review, we have summarized the current understanding of toxoplasmosis. Full article
Show Figures

Figure 1

12 pages, 833 KB  
Article
Efficacy of Heterologous Vaccination Using Virus-Like Particles and Vaccinia Virus Containing MIC8 and AMA1 Proteins of Toxoplasma gondii
by Hae-Ji Kang and Fu-Shi Quan
Vaccines 2025, 13(8), 862; https://doi.org/10.3390/vaccines13080862 - 15 Aug 2025
Viewed by 326
Abstract
Background: Toxoplasma gondii (T. gondii) infection causes serious diseases in immunocompromised patients and causes congenital toxoplasmosis in infants. T. gondii microneme protein 8 (MIC8) and apical membrane antigen 1 (AMA1) are essential proteins involved in parasitic invasion. Methods: In this [...] Read more.
Background: Toxoplasma gondii (T. gondii) infection causes serious diseases in immunocompromised patients and causes congenital toxoplasmosis in infants. T. gondii microneme protein 8 (MIC8) and apical membrane antigen 1 (AMA1) are essential proteins involved in parasitic invasion. Methods: In this study, we generated virus-like particles (VLPs) and recombinant vaccinia virus (rVV) containing MIC8 or AMA1 proteins. Vaccine efficacy was evaluated in mice (BALB/c) upon challenge infection with T. gondii ME49. Results: Intramuscular immunization with heterologous vaccines (rVV + VLPs; rVV for prime and VLPs for boost) elicited T. gondii-specific IgG antibody responses in mice. Four weeks after the boost, all mice were orally challenged with T. gondii ME49, and protective immunity was assessed. The responses of antibody-secreting cells for IgG2a and IgG2b and those of memory B cells and CD4+ and CD8+ T cells were higher in the rVV + VLP group than in the VLP + VLP group. The rVV + VLP group exhibited a significant reduction in cyst count in the brain. Conclusions: These findings indicate that heterologous vaccination with vaccinia viruses and VLPs improves vaccine efficacy. Full article
(This article belongs to the Special Issue Virus-Like Particle Vaccine Development)
Show Figures

Figure 1

15 pages, 3077 KB  
Article
Cascade CRISPR/cas Enables More Sensitive Detection of Toxoplasma gondii and Listeria monocytogenes than Single CRISPR/cas
by Dawei Chen, Min Sun, Bingbing Li, Jian Ma, Qinjun Zhang, Wanli Yin, Jie Li, Mingyue Wei, Liang Liu, Pengfei Yang and Yujuan Shen
Microorganisms 2025, 13(8), 1896; https://doi.org/10.3390/microorganisms13081896 - 14 Aug 2025
Viewed by 267
Abstract
Foodborne pathogens represent a class of pathogenic microorganisms capable of causing food poisoning or serving as foodborne vectors, constituting a major source of food safety concerns. With increasing demands for rapid diagnostics, conventional culture-based methods and PCR assays face limitations due to prolonged [...] Read more.
Foodborne pathogens represent a class of pathogenic microorganisms capable of causing food poisoning or serving as foodborne vectors, constituting a major source of food safety concerns. With increasing demands for rapid diagnostics, conventional culture-based methods and PCR assays face limitations due to prolonged turnaround times and specialized facility requirements. While CRISPR-based detection has emerged as a promising rapid diagnostic platform, its inherent inability to detect low-abundance targets necessitates coupling with isothermal amplification, thereby increasing operational complexity. In this study, we preliminarily developed a novel amplification-free Cascade-CRISPR detection system utilizing a hairpin DNA amplifier. This method achieves detection sensitivity as low as 10 fM (82 parasites/μL) for DNA targets within 30 min without requiring pre-amplification, with background signal suppression achieved through optimized NaCl concentration. Validation using artificially contaminated food samples demonstrated the platform’s robust performance for both Toxoplasma gondii (T. gondii) and Listeria monocytogenes (L. monocytogenes) detection, confirming broad applicability. In summary, this study preliminarily establishes an amplification-free Cascade-CRISPR detection platform that achieves high sensitivity and rapid turnaround, demonstrating strong potential for on-site screening of foodborne pathogens. Full article
(This article belongs to the Section Food Microbiology)
Show Figures

Figure 1

10 pages, 1901 KB  
Article
Bovine Viral Diarrhea Virus-1 (Pestivirus bovis) Associated with Stillborn and Mummified Fetuses in Farmed White-Tailed Deer (Odocoileus virginianus) in Florida
by An-Chi Cheng, Emily DeRuyter, Pedro H. de Oliveira Viadanna, Zoe S. White, John A. Lednicky, Samantha M. Wisely, Kuttichantran Subramaniam and Juan M. Campos Krauer
Viruses 2025, 17(8), 1104; https://doi.org/10.3390/v17081104 - 12 Aug 2025
Viewed by 807
Abstract
Bovine viral diarrhea virus (BVDV) is a globally significant pathogen affecting both domestic livestock and wildlife, including white-tailed deer (WTD; Odocoileus virginianus). While experimental infections have demonstrated WTD susceptibility to BVDV, natural infections and associated reproductive outcomes remain scarcely documented. Here, we [...] Read more.
Bovine viral diarrhea virus (BVDV) is a globally significant pathogen affecting both domestic livestock and wildlife, including white-tailed deer (WTD; Odocoileus virginianus). While experimental infections have demonstrated WTD susceptibility to BVDV, natural infections and associated reproductive outcomes remain scarcely documented. Here, we report the first confirmed case of naturally occurring BVDV-1 infection associated with fetal mummification in farmed WTD in Florida. A two-year-old doe experienced a stillbirth involving two mummified fetuses, which were submitted for necropsy and laboratory diagnostics. Gross findings included diarrhea and underdeveloped eyes in the fetuses, along with small white nodules indicative of amnion nodosum. While not harmful, this condition suggests underlying fetal compromise or intrauterine stress. Virus isolation using Vero E6 and bovine turbinate cell lines, along with a reverse transcription PCR (RT-PCR) assay specifically developed in this study, confirmed the presence of BVDV-1 (Pestivirus bovis) RNA in both maternal and fetal samples, suggesting vertical transmission. Sanger sequencing of RT-PCR amplicons further verified the virus species as BVDV-1. Differential diagnostics for other pathogens, including bluetongue virus, epizootic hemorrhagic disease virus, Mycobacterium spp., and Toxoplasma gondii, were negative. These findings underscore the importance of using biosecurity measures and including BVDV in the differential diagnosis of abortions to reduce the risk of BVDV transmission and potential outbreaks on deer farms, particularly those close to cattle operations. The molecular tools developed in this study provide a robust framework for improved detection and monitoring of BVDV in both wildlife and livestock populations. Full article
(This article belongs to the Section Animal Viruses)
Show Figures

Graphical abstract

14 pages, 2099 KB  
Article
Immunogenicity and Protective Efficacy of a Recombinant Toxoplasma gondii GRA12 Vaccine in Domestic Cats
by Jinru Yang, Linchong Nie, Yining Song, Zipeng Yang, Liulu Yang, Hongjie Ren, Wenhao Li, Yasser Mahmmod, Xiu-Xiang Zhang, Ziguo Yuan, Hao Yuan and Yan Zhang
Vaccines 2025, 13(8), 851; https://doi.org/10.3390/vaccines13080851 - 11 Aug 2025
Viewed by 386
Abstract
Background: Toxoplasma gondii (T. gondii) is a significant opportunistic zoonotic protozoan, presenting a substantial risk to human health and livestock. Consequently, the development of an effective vaccine against toxoplasmosis is imperative. This study focuses on the GRA12 protein as a [...] Read more.
Background: Toxoplasma gondii (T. gondii) is a significant opportunistic zoonotic protozoan, presenting a substantial risk to human health and livestock. Consequently, the development of an effective vaccine against toxoplasmosis is imperative. This study focuses on the GRA12 protein as a target for developing a recombinant protein vaccine, with its efficacy evaluated through immunization trials in cats. Methods: We expressed recombinant GRA12 protein in E. coli and immunized cats with the purified antigen. The cats were categorized into four groups: G1 (PBS control), G2 (ISA 201 adjuvant alone), G3 (rGRA12 vaccine), and G4 (rGRA12 combined with ISA 201 adjuvant). All cats underwent subcutaneous immunizations on days 0, 14, and 28. Subsequently, serum levels of IgG (including IgG1 and IgG2a subclasses) and cytokines (IFN-γ, IL-2, TNF-α, IL-4, IL-10) were measured by enzyme-linked immunosorbent assay (ELISA). Two weeks after the third immunization (42 DPI), each cat was intraperitoneally infected with 1 × 106T. gondii RH tachyzoites. Oocyst shedding, survival duration, and T. gondii burden were monitored to assess vaccine-induced immunity. Results: The results indicate that immunization with recombinant rGRA12 protein significantly elevated IgG, IgG1, and IgG2a antibody levels in cats. G4 displayed elevated IgG levels post-immunization compared to G1 and G2, with an IgG1/IgG2a ratio > 1, indicating a mixed Th1/Th2 immune response. G4 also showed significantly increased IFN-γ, IL-2, TNF-α, and IL-4 levels compared to G1 (p < 0.05), while IL-10 remained unchanged. After T. gondii infection, total oocyst counts were 4.61 × 106 (G1), 4.49 × 106 (G2), 3.58 × 106 (G3), and 2.59 × 106 (G4), with G3/G4 showing 20.1–27.9% reduction relative to G1 (p < 0.05). Survival analysis revealed that groups G3 and G4 exhibited significantly longer median survival times (38 and 60 days, respectively; G4 with no mortality) compared to G1 and G2 (19 and 26 days, respectively). Additionally, parasite burdens in the brain, heart, lungs, liver, and spleen were significantly reduced in G3/G4 compared to G1/G2 (p < 0.01). Conclusions: In summary, the recombinant GRA12 vaccine significantly enhanced host survival and reduced parasite burden, demonstrating its potential as an effective toxoplasmosis vaccine candidate. These findings provide valuable data for future toxoplasmosis vaccine development. Full article
(This article belongs to the Special Issue The Development of Vaccine Against Parasite Infection)
Show Figures

Figure 1

14 pages, 2079 KB  
Article
Emerging Trends in Toxoplasmosis Seroepidemiology in Childbearing-Aged Women in Croatia, 2015–2024
by Mario Sviben, Klara Barbić, Maja Bogdanić, Ema Reicher, Sara Glavaš, Dan Navolan, Ana Sanković, Tomislav Meštrović, Ivan Mlinarić, Simona Vlădăreanu, Radu Vlădăreanu and Tatjana Vilibić-Čavlek
Pathogens 2025, 14(8), 796; https://doi.org/10.3390/pathogens14080796 - 8 Aug 2025
Viewed by 341
Abstract
Childbearing-aged and pregnant women represent a risk group for Toxoplasma gondii infection due to possible transplacental transmission resulting in congenital toxoplasmosis. We analyzed the seroepidemiological trends of toxoplasmosis in Croatia over ten years (2015–2024). A total of 2791 childbearing-aged and pregnant women were [...] Read more.
Childbearing-aged and pregnant women represent a risk group for Toxoplasma gondii infection due to possible transplacental transmission resulting in congenital toxoplasmosis. We analyzed the seroepidemiological trends of toxoplasmosis in Croatia over ten years (2015–2024). A total of 2791 childbearing-aged and pregnant women were included. Toxoplasma gondii-specific IgM/IgG antibodies were detected using an enzyme-linked fluorescence assay. Samples with positive IgM and IgG antibodies were tested for IgG avidity. IgG antibodies were detected in 695 (24.9%) participants, while acute toxoplasmosis (IgM antibodies and low avidity IgG antibodies) was confirmed in 32 (1.2%) of participants. The IgG seroprevalence showed a declining trend over the years. Residents of suburban/rural areas were more often seropositive than those in urban areas (31.4 vs. 22.3%). Logistic regression analysis revealed that year of testing, age, and settlement were associated with the risk of seropositivity. For each later calendar year, the log odds of being IgG-positive decreased, while for each additional year of age, the log odds increased. Residence in an urban area was associated with lower log odds. The region was not a significant predictor in the logistic regression. The differences in seropositivity observed across regions can be mainly attributed to Pannonian Croatia, which showed significantly higher odds of IgG seropositivity. Data about the toxoplasma serological status is useful for planning prevention campaigns. Full article
(This article belongs to the Special Issue Emerging and Neglected Pathogens in the Balkans)
Show Figures

Figure 1

12 pages, 579 KB  
Article
In Vivo Safety and Efficacy of Thiosemicarbazones in Experimental Mice Infected with Toxoplasma gondii Oocysts
by Manuela Semeraro, Ghalia Boubaker, Mirco Scaccaglia, Dennis Imhof, Maria Cristina Ferreira de Sousa, Kai Pascal Alexander Hänggeli, Anitha Löwe, Marco Genchi, Laura Helen Kramer, Alice Vismarra, Giorgio Pelosi, Franco Bisceglie, Luis Miguel Ortega-Mora, Joachim Müller and Andrew Hemphill
Biomedicines 2025, 13(8), 1879; https://doi.org/10.3390/biomedicines13081879 - 1 Aug 2025
Cited by 1 | Viewed by 325
Abstract
Background: Toxoplasma gondii is a globally widespread parasite responsible for toxoplasmosis, a zoonotic disease with significant impact on both human and animal health. The current lack of safe and effective treatments underscores the need for new drugs. Earlier, thiosemicarbazones (TSCs) and their [...] Read more.
Background: Toxoplasma gondii is a globally widespread parasite responsible for toxoplasmosis, a zoonotic disease with significant impact on both human and animal health. The current lack of safe and effective treatments underscores the need for new drugs. Earlier, thiosemicarbazones (TSCs) and their metal complexes have shown promising activities against T. gondii. This study evaluated a gold (III) complex C3 and its TSC ligand C4 for safety in host immune cells and zebrafish embryos, followed by efficacy assessment in a murine model for chronic toxoplasmosis. Methods: The effects on viability and proliferation of murine splenocytes were determined using Alamar Blue assay and BrdU ELISA, and potential effects of the drugs on zebrafish (Danio rerio) embryos were detected through daily light microscopical inspection within the first 96 h of embryo development. The parasite burden in treated versus non-treated mice was measured by quantitative real-time PCR in the brain, eyes and the heart. Results: Neither compound showed immunosuppressive effects on the host immune cells but displayed dose-dependent toxicity on early zebrafish embryo development, suggesting that these compounds should not be applied in pregnant animals. In the murine model of chronic toxoplasmosis, C4 treatment significantly reduced the parasite load in the heart but not in the brain or eyes, while C3 did not have any impact on the parasite load. Conclusions: These results highlight the potential of C4 for further exploration but also the limitations of current approaches in effectively reducing parasite burden in vivo. Full article
(This article belongs to the Section Microbiology in Human Health and Disease)
Show Figures

Figure 1

11 pages, 2391 KB  
Article
A Major Facilitator Superfamily Transporter Is Critical for the Metabolism and Biogenesis of the Apicoplast
by Yumeng Liang, Wei Qi, Jiawen Fu and Honglin Jia
Pathogens 2025, 14(8), 763; https://doi.org/10.3390/pathogens14080763 - 1 Aug 2025
Viewed by 289
Abstract
The apicoplast is a highly specialized organelle in the biosynthesis of essential metabolites in most of the apicomplexan protozoa. This organelle is surrounded by four layers of membranes. However, the molecular mechanisms mediating transmembrane transport are not yet fully understood. In this study, [...] Read more.
The apicoplast is a highly specialized organelle in the biosynthesis of essential metabolites in most of the apicomplexan protozoa. This organelle is surrounded by four layers of membranes. However, the molecular mechanisms mediating transmembrane transport are not yet fully understood. In this study, we conducted a phenotypic analysis to investigate the role of a major facilitator superfamily transporter (TgApMFS1) in the survival of the parasite. The results indicated that TgApMFS1 is critical for the survival of Toxoplasma gondii in cell culture conditions. Further analysis indicated that these transporters are crucial for the biogenesis of organelles and the metabolic processes of parasite. Full article
(This article belongs to the Section Parasitic Pathogens)
Show Figures

Figure 1

15 pages, 319 KB  
Review
Toxoplasma gondii at the Host Interface: Immune Modulation and Translational Strategies for Infection Control
by Billy J. Erazo Flores and Laura J. Knoll
Vaccines 2025, 13(8), 819; https://doi.org/10.3390/vaccines13080819 - 31 Jul 2025
Viewed by 601
Abstract
Toxoplasma gondii is an intracellular protozoan found worldwide that is capable of infecting nearly all warm-blooded animals, including humans. Its parasitic success lies in its capacity to create chronic infections while avoiding immune detection, altering host immune responses, and disrupting programmed cell death [...] Read more.
Toxoplasma gondii is an intracellular protozoan found worldwide that is capable of infecting nearly all warm-blooded animals, including humans. Its parasitic success lies in its capacity to create chronic infections while avoiding immune detection, altering host immune responses, and disrupting programmed cell death pathways. This review examines the complex relationship between T. gondii and host immunity, focusing on how the parasite influences innate and adaptive immune responses to survive in immune-privileged tissues. We present recent findings on the immune modulation specific to various parasite strains, the immunopathology caused by imbalanced inflammation, and how the parasite undermines host cell death mechanisms such as apoptosis, necroptosis, and pyroptosis. These immune evasion tactics enable prolonged intracellular survival and pose significant challenges for treatment and vaccine development. We also review advancements in therapeutic strategies, including host-directed approaches, nanoparticle drug delivery, and CRISPR-based technologies, along with progress in vaccine development from subunit and DNA vaccines to live-attenuated candidates. This review emphasizes the importance of T. gondii as a model for chronic infections and points out potential avenues for developing innovative therapies and vaccines aimed at toxoplasmosis and similar intracellular pathogens. Full article
(This article belongs to the Special Issue Intracellular Parasites: Immunology, Resistance, and Therapeutics)
12 pages, 1798 KB  
Article
Protective Efficacy Induced by Virus-like Particles Expressing Dense Granule Protein 5 of Toxoplasma gondii
by Su In Heo, Hae-Ji Kang, Jie Mao, Zhao-Shou Yang, Md Atique Ahmed and Fu-Shi Quan
Vaccines 2025, 13(8), 787; https://doi.org/10.3390/vaccines13080787 - 24 Jul 2025
Viewed by 485
Abstract
Background: Toxoplasma gondii (T. gondii) causes severe disease in immunocompromised individuals and pregnant women, underscoring the urgent need for effective vaccines against toxoplasmosis. The dense granule protein 5 (GRA5) of T. gondii plays a key role in parasitic cyst formation. [...] Read more.
Background: Toxoplasma gondii (T. gondii) causes severe disease in immunocompromised individuals and pregnant women, underscoring the urgent need for effective vaccines against toxoplasmosis. The dense granule protein 5 (GRA5) of T. gondii plays a key role in parasitic cyst formation. Methods: This study evaluated the protective immune responses induced by a virus-like particle (VLP) vaccine expressing the T. gondii-derived antigen GRA5 in a mouse model challenged with the ME49 strain of T. gondii. GRA5 VLPs were generated using a baculovirus expression system, and VLP formation was confirmed by Western blotting and visualized using transmission electron microscopy. Mice were intranasally immunized with GRA5 VLPs three times at 4-week intervals to induce immune responses, followed by infection with T. gondii ME49. Results: Intranasal immunization with GRA5 VLPs induced parasite-specific IgG antibody responses in the serum and both IgG and IgA antibody responses in the brain. Compared to the non-immunized group, immunized mice exhibited significantly higher levels of germinal center B cells and antibody-secreting cell responses. Moreover, the VLP vaccine suppressed the production of IFN-γ and IL-6 cytokines, leading to a significant reduction in brain inflammation and decreased cyst counts following lethal challenge with T. gondii ME49 infection. Conclusion: These findings suggest that the GRA5 VLP vaccine derived from T. gondii elicits a protective immune response, highlighting its potential as an effective vaccine candidate against toxoplasmosis. Full article
(This article belongs to the Special Issue Research on Immune Response and Vaccines: 2nd Edition)
Show Figures

Figure 1

14 pages, 503 KB  
Article
Toxoplasma gondii Seroprevalence and Associated Risk Factors in Psychiatric Patients Diagnosed with Moderate and Major Depression from Western Romania: A Case—Control Retrospective Study
by Alin Gabriel Mihu, Alexander Tudor Olariu, Ligia Elisaveta Piros, Sebastian Grada, Ana Alexandra Ardelean, Sergiu Adrian Sprintar, Daniela Adriana Oatis, Rodica Lighezan and Tudor Rares Olariu
Life 2025, 15(8), 1157; https://doi.org/10.3390/life15081157 - 22 Jul 2025
Viewed by 467
Abstract
The protozoan parasite Toxoplasma gondii (T. gondii) has been implicated in various neuropsychiatric disorders, including depression. Our aim in this study was to assess the seroprevalence of T. gondii IgG antibodies as well as potential risk factors associated with seropositivity in [...] Read more.
The protozoan parasite Toxoplasma gondii (T. gondii) has been implicated in various neuropsychiatric disorders, including depression. Our aim in this study was to assess the seroprevalence of T. gondii IgG antibodies as well as potential risk factors associated with seropositivity in patients with depression compared to healthy blood donors. This seroepidemiological study included 230 participants from Western Romania, divided equally into two groups: 115 patients diagnosed with depressive disorders which represented the study group and 115 age and gender-matched healthy blood donors, representing the control group. A structured questionnaire was used to assess risk factors potentially linked to T. gondii infection. The T. gondii IgG antibodies overall seroprevalence was significantly higher in the depression group (70.43%) compared to the control group (45.22%) (OR = 2.89; 95% CI: 1.68–4.97; p < 0.001). Higher seropositivity was noted in patients aged 50–59, 60+ years and in females. Patients with lower educational attainment showed significantly increased odds of T. gondii seropositivity (72.29% vs. 44.3%, OR = 3.28; 95% CI: 1.71–6.31; p < 0.001) compared with the control group. Stratification by ICD-10 diagnostic subtypes revealed significantly higher seropositivity in all categories, with the strongest association in patients with recurrent severe depressive episodes without psychotic symptoms (F33.2) (81.25%, OR = 3.5; 95% CI: 1.51–8.13; p = 0.004). These findings suggest a possible link between T. gondii infection and depression, particularly in relation to disease severity and sociodemographic factors. To our knowledge, this is the first study to investigate T. gondii seroprevalence and associated risk factors in Romanian patients with depression, providing a foundation for future longitudinal and preventive research. Full article
(This article belongs to the Special Issue Trends in Microbiology 2025)
Show Figures

Figure 1

Back to TopTop